**Epidemiology of whiplash**

Space restrictions prohibit a comprehensive refutation of the uneven treatment of the whiplash literature presented by Ferrari and Russell. They fiercely interrogate research that does not support their view, yet uncritically embrace literature favouring their pre-conceptions. Central to their argument is the assertion that there are different rates of chronic whiplash in different countries, and that the “medical” related damage cannot account for the wide differences.

A valid comparison between the prevalence of any condition in two places would require that it is measured in the same way. Balla’s study comparing Singapore and Australia was little more than anecdotal from interviews of selected Singaporean doctors compared with the data from Australia. Such data may be fatally corrupted by recall, case selection, sampling, and expectation bias.

Caution should be observed in comparing insurance claim rates between countries. There is no international consistency in notification of accidents or insurance or compensation procedures. Conclusions drawn from such comparisons are unsustainable and subject to the ecological fallacy. The frailty of using insurance claims as a surrogate for the incidence of injury does not seem to have bothered Ferrari and Russell. A claim is a behaviour arising from a combination of motivation, enabling circumstances, perceived benefits, costs, social norms, peer and family pressure, and fear of current or future pain and disability—all factors extraneous to the injury itself. The Victorian experience in Australia is particularly pertinent. Fewer claims for whiplash were noted after the introduction of legislation, treating bureaucratic barriers, disincentives, and up-front costs for potential claimants. Some then concluded that whiplash is a behaviour and not an injury.1 A more sober view is that if it is a claim, fewer people will make one. To extrapolate beyond this is unjustifiable: the apparent change in incidence may simply be due to reporting bias.

This study has been used to argue that chronic symptoms after whiplash do not occur in communities lacking a compensation system.2 However, only 31 patients developed any neck pain as a result of the accident, with none reporting chronic pain. The 95% confidence limits of this estimate range up to 10%. Therefore, the data are consistent with a rate of chronicity of up to 10%. The German and later Lithuanian studies, on which Ferrari and Russell rely, also lack the power to detect a significant chronicity rate.

Magnetic resonance imaging (MRI) is insensitive to abnormalities of the soft tissue and bone scan studies have shown potentially painful pathology. In considering our studies of chronic zygapophysial joint pain after whiplash, Ferrari and Russell argue that our patients were unrepresentative. However, most of our patients developed pain within 72 hours of the accident and were passengers or drivers of motor vehicles.3 They were intentionally representative and typical of patients with chronic whiplash. Radanov’s work is criticised on the basis that they “selectively gathered 117 patients through advertisement”. This would imply that patients answered advertisements they were not paid, producing a biased sample. However, the advertisement was in a medical journal, seeking doctors to enrol participants, producing a representative sample. Ferrari and Russell have used these studies in a previous, apparently accepting the methodology then.4 These flaws alone raise grounds for concern that the opinions of Ferrari and Russell are not responsibly based on an appraisal of the literature and will raise alarm and reinforce prejudice against genuinely afflicted patients.

**LES BARNSLY**

*Senior Lecturer in Rheumatology, University of Sydney, Department of Rheumatology, Concord Hospital, Concord NSW 2139, Australia*

Email: levi@card.crg.cs.nsw.gov.au

---

7 Schraeder H, Obelieniene D, Bovim G, Surkieniene D, Miseviciene I, et al. Magnetic resonance imaging (MRI) is insensitive to abnormalities of the soft tissue and bone scan studies have shown potentially painful pathology.
Matters arising, Letters, Correction

We thank Drs Barnsley and Bogduk for their comments. Dr Barnsley reiterates a dualistic (mind-body) approach that we have been trying to blur and indeed do away with for various reasons. We do not accept that chronic pain is all in the mind, nor all in the body. We also believe, to use her term, that these patients are “genuinely a part of the problem.” Yet, until it is thoroughly understood the behaviour that promotes chronic pain, society in response to acute whiplash. Understanding the behaviour that promotes chronic pain is a major social and economic burden, with more than 50% of accident victims reporting chronic pain six months after the accident.

The patients of Dr Bogduk’s study represent merely the tip of a large iceberg. Thus new paradigms are necessary to understand why some subjects recover within six weeks or fewer and others do not. As no one has suggested that Lithuanians, Greeks, and Germans have a different anatomy, Dr Barnsley suggests that understanding what is important to support chronic pain patients in each country is a massive challenge. The studies in Lithuania, Greece, and Germany cannot rule out the possibility that a small number of subjects having chronic pain and disability, but they do show that recovery (as measured by absence of symptoms and return to normal activities, as well as other patient centred outcomes) occurs in 90–95% of subjects in six weeks or less. It is this fact that compels us to question the basis for chronic pain in say, Canada. We find that whiplash in Canada (and reportedly in many other countries) is a massive social and economic burden, with more than 50% of accident victims reporting chronic pain six months after the accident.

The purpose of our model is to develop discussion on research questions and develop a better understanding of the complex interplay of factors that contribute to chronic pain. The purpose of our model is to develop discussion on research questions and develop a better understanding of the complex interplay of factors that contribute to chronic pain.

We do not accept that chronic pain is all in the mind, nor all in the body. We also believe, to use her term, that these patients are “genuinely a part of the problem.” Yet, until it is thoroughly understood the behaviour that promotes chronic pain, society in response to acute whiplash. Understanding the behaviour that promotes chronic pain is a major social and economic burden, with more than 50% of accident victims reporting chronic pain six months after the accident.

The patients of Dr Bogduk’s study represent merely the tip of a large iceberg. Thus new paradigms are necessary to understand why some subjects recover within six weeks or fewer and others do not. As no one has suggested that Lithuanians, Greeks, and Germans have a different anatomy, Dr Barnsley suggests that understanding what is important to support chronic pain patients in each country is a massive challenge.

The studies in Lithuania, Greece, and Germany cannot rule out the possibility that a small number of subjects having chronic pain and disability, but they do show that recovery (as measured by absence of symptoms and return to normal activities, as well as other patient centred outcomes) occurs in 90–95% of subjects in six weeks or less. It is this fact that compels us to question the basis for chronic pain in say, Canada. We find that whiplash in Canada (and reportedly in many other countries) is a massive social and economic burden, with more than 50% of accident victims reporting chronic pain six months after the accident.

The purpose of our model is to develop discussion on research questions and develop a better understanding of the complex interplay of factors that contribute to chronic pain. The purpose of our model is to develop discussion on research questions and develop a better understanding of the complex interplay of factors that contribute to chronic pain.

We do not accept that chronic pain is all in the mind, nor all in the body. We also believe, to use her term, that these patients are “genuinely a part of the problem.” Yet, until it is thoroughly understood the behaviour that promotes chronic pain, society in response to acute whiplash. Understanding the behaviour that promotes chronic pain is a major social and economic burden, with more than 50% of accident victims reporting chronic pain six months after the accident.
large, that this is part of the problem, this practice is unlikely to change.

By setting forth this model we can now investigate it. We are making efforts to do this, and we hope that quality researchers such as Drs Barnsley and Bogduk will engage in such efforts as well.

R FERRARI
Department of Rheumatic Diseases, 562 Heritage Medical Research Centre
University of Alberta
Edmonton, Alberta
Canada T6G 2S2

A S RUSSELL


R Rheumatoid arthritis, poverty, and smoking

Maiden et al raise a number of important and interesting points in their paper.1 Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients?2

They have observed that mortality in rheu-matoid arthritis (RA) correlated with social groupings on the west coast of Scotland. Patients with RA of the lowest socioeconomic classes have an increased mortality when compared with patients of a higher socioeconomic class. Moreover, RA was more prevalent in patients with RA of lower socioeconomic class. We propose that these two important observations can both be explained by cigarette smoking.

The authors commented that cigarette smoking was more prevalent in the patients with RA of lower socioeconomic class in their study. In Britain there is a marked difference in smoking prevalence between social classes. In the 1996 census 41% of lower social class men (social class 4) were current smokers, with only 12% of men in the highest social class (social class 1) currently smoking.3

Cigarette smoking kills 120 000 people a year in Britain. Most of these deaths are as a result of cardiovascular disease, respiratory disease, and lung cancer. Maiden et al observed that 65% of the deaths in their study occurred as a result of these diseases. Current data show that continued cigarette smoking throughout adult life doubles age-specific mortality rates and is an adverse influence in late middle age.4 Cigarette smoking is associated with an increased risk of RA in both men and women. The increased mortality seen in patients with RA of low socioeconomic status could be explained in part by cigarette smoking, and that cigarette smoking itself might have contributed to the excess RA seen in the most socially deprived.

Since the poorest in our society appear to have an increased risk of RA, studies designed to identify risk factors for RA may best be focused on those with the highest risk. Ciga-rette smoking may be especially important to study, because it is the most powerful risk factor seen in the poorest socioeconomic popula-tion with RA. Laudable attempts to study the epidemiology of RA in Britain have been set up. One example is the Norwich Arthritis Register. However, we would suggest such populations, in which there are a large proportion of higher socioeconomic groups, are unrepresentative of the large industrial cities in Britain. In 239 patients with RA in the Merseyside area under hospital follow up, the social class of our patients was identified using the Office of National Statistics classification of occupations. The patients with RA in Merseyside were of significantly lower social class than the patients with inflammatory polyarthritis studied in Norfolk. Table 1 summarises these findings. If the findings reported by Maiden et al are supported by further studies, there would seem to be significant differences in inci-dence, severity, and mortality in RA accord-ing to socioeconomic profiles. This would mean that increased resources should be allocated to regions of greatest need and not, as at present, to areas where socioeconomic class is highest, such as the south of England.

D HUTCHINSON
R J MOOTS
Department of Rheumatology,
University Hospital Aintree,
Longmoor Lane
Liverpool L9 7AL, UK

Authors’ reply to Dr Radanov

Dr Radanov’s expressed concerns and cry for auto-da-fé are based on his perception that our biopsychosocial model is one of maligin-ering as an explanation for the late whiplash syndrome. As we have explicitly stated, in both our article and in a previous inquirous review on this topic, we reject a model based on malingering and we consider this to be a rare or uncommon presentation.5 Dr Radanov’s concerns are therefore misplaced. That Dr Radanov is unable to appreciate how our biopsychosocial model presents alterna-tives to the otherwise unhelpful, unidimen-sional, and dichotomous approaches taken by himself and others is a problem for him, but one which we cannot ameliorate in the space available. We thus refer him to a more comprehensive resource.6

Once again, we reject the view that the chronic pain of whiplash is due to an enigmatic and inexplicable chronic injury, and we simultaneously reject the view that the best explanation (or even a common explanation) for the late whiplash syndrome is maligin-ering or psychological models that place the pain “all in one’s head”. The biopsychosocial model includes physical sources for pain, and incorporates psychosocial factors to explain both the severity and attribution of the pain, as well as further behaviour enacted upon this substrate of otherwise benign physical sources of pain. Thus we maintain that the most helpful focus of discussion and research should be on identifying how the various elements of the biopsychosocial model explain the variance in epidemiology of the late whiplash syndrome, and why, even within a given culture some accident victims recover quickly and others do not. Dr Radanov’s views may be coloured by the relatively benign nature of the problem he sees in Swit-zerland. Even with an advertising campaign to recruit subjects, the Swiss outcomes were very much better than those currently being described in North America. We maintain that the Swiss effort at understanding these issues has been a start, but is a mere footstep in a much longer journey of inquisition.


Social class
Social class
Social class
1–2 No (%) 3N–M§ No (%) 4–5 No (%)

Inflammatory polyarthritis cases Norfolk and Norwich (154) 51 (33) 73 (47) 30 (19)
RA cases Merseyside (239) 28 (12)* 87 (36)** 124 (52)*

* p<0.0001; ** p<0.05.
† Social class based on the Office of National Statistics classification of occupations.7
‡ N = non-manual; M = manual.

Table 1
We observed a higher mortality rate among patients with rheumatoid arthritis (RA) living in deprived areas relative to those living in affluent areas. Our methodology did not determine the social class of individual patients according to the Office of National Statistics classification of occupations. Nevertheless, whether measured by income, occupation, educational level, social class, or ecological variables such as the Carstairs score, socioeconomic deprivation has been shown to influence health.\(^1\) In addition, we observed that there were more patients with RA living in deprived areas than in the general population in Scotland. Although this may result from a higher prevalence of RA among the lower socioeconomic classes, this conclusion cannot be drawn overtly from our study. Patients with RA are more likely to live in areas of affluence and deprivation would prove valuable in determining the epidemiology of RA.

Out of a cohort 40% of the most affluent group (Carstairs 1 and 2), 45% of Carstairs 4, 5, and 6, and 65% of the most deprived group (Carstairs 6 and 7) were current smokers; figures much higher than the 1996 census figures of 12% and 41% for social classes 1 and 2 respectively. This difference may reflect the fact that our patients were recruited a decade earlier (1984–85), but there are also social/cultural differences between Scotland and the United Kingdom as a whole. The prevalence of smoking in Scotland from the Scottish Health Survey 1995 was 23% in social classes 1 and 2 and 49% in social classes 4 and 5. Although differences in mortality rates according to smoking with RA according to socioeconomic deprivation can be explained, in part, by differences in the prevalence of smoking, the observed difference of deprivation in RA is less easily accounted for by smoking. Functional ability is an important outcome measure in RA and is a predictor of mortality in this disease.\(^7\)

The Scottish Health Survey 1995 showed that there were differences according to social class in other important determinants of health, including diet, alcohol consumption, obesity, hypertension, lung function, fibrinogen levels, general health perception, and psychological state. Further research is required to establish the relative importance of these and other factors in determining the influence of socioeconomic deprivation on outcome and mortality in RA and other chronic diseases. The factors which can be modified most effectively to reduce the inequalities in health outcome also require investigation.

If our findings are supported by further studies the socioeconomic status of populations should influence resource allocation. In addition, these important factors should assist rheumatologists when deciding which patients with RA should receive more intensive, multidisciplinary intervention.

---

Authors’ reply

We welcome the letter entitled “Rheumatoid arthritis, poverty, and smoking” in response to our article “Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients?” The importance of smoking as a contributor to the influence of socioeconomic deprivation on mortality is rightly emphasised. However, as Black has pointed out eloquently, smoking alone does not account for the excess mortality seen among lower socioeconomic groups.\(^1\) In addition, we observed that there were more patients with RA living in deprived areas than in the general population in Scotland. Although this may result from a higher prevalence of RA among the lower socioeconomic classes, this conclusion cannot be drawn overtly from our study. Patients with RA are more likely to live in areas of affluence and deprivation would prove valuable in determining the epidemiology of RA.

According to our data, 40% of the most affluent group (Carstairs 1 and 2), 45% of Carstairs 4, 5, and 6, and 65% of the most deprived group (Carstairs 6 and 7) were current smokers; figures much higher than the 1996 census figures of 12% and 41% for social classes 1 and 2 respectively. This difference may reflect the fact that our patients were recruited a decade earlier (1984–85), but there are also social/cultural differences between Scotland and the United Kingdom as a whole. The prevalence of smoking in Scotland from the Scottish Health Survey 1995 was 23% in social classes 1 and 2 and 49% in social classes 4 and 5. Although differences in mortality rates according to smoking with RA according to socioeconomic deprivation can be explained, in part, by differences in the prevalence of smoking, the observed difference of deprivation in RA is less easily accounted for by smoking. Functional ability is an important outcome measure in RA and is a predictor of mortality in this disease.\(^7\)

The Scottish Health Survey 1995 showed that there were differences according to social class in other important determinants of health, including diet, alcohol consumption, obesity, hypertension, lung function, fibrinogen levels, general health perception, and psychological state. Further research is required to establish the relative importance of these and other factors in determining the influence of socioeconomic deprivation on outcome and mortality in RA and other chronic diseases. The factors which can be modified most effectively to reduce the inequalities in health outcome also require investigation.

If our findings are supported by further studies the socioeconomic status of populations should influence resource allocation. In addition, these important factors should assist rheumatologists when deciding which patients with RA should receive more intensive, multidisciplinary intervention.

---

Diagnostic evaluation of classification criteria for RA and reactive arthritis

We read with interest the recent article by Hülsemann and Zeidler, which reports that the 1987 American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis (RA) were evaluated for their ability to identify patients with a clinical diagnosis of RA among 217 patients referred to an early arthritis clinic. The authors concluded that the 1987 ACR criteria can be used to make a diagnosis of RA in this setting.

In our study, the “gold standard” against which the criteria were compared was an “expert diagnosis” made by one of the authors when the patient was first seen (within one year of symptom onset). The main difficulty faced in our study was that patients with early disease is that patients who ultimately develop RA appear clinically similar to those who have self limiting disease or other forms of inflammatory arthritis. It is therefore too early to make an accurate diagnosis at this stage. More importantly, RA is a heterogeneous disease with a prognosis which varies from complete symptom remission to severe disability. Therefore simply categorizing patients into those who do and do not have “RA” is not necessarily important when considering which patients require early treatment. Although the authors made a clinical diagnosis without using the classification criteria, we ascertained from case note review. It is therefore more appropriate in a group with early synovitis to assess the criteria longitudinally at follow up rather than simply at baseline.\(^3\) In the study by Hülsemann and Zeidler we were given no information about how or when the criteria were applied apart from that they were applied “retrospectively”.

We agree with Hülsemann and Zeidler that there is a need to “…differentiate RA as early as possible from the often benign and self-limited forms of undifferentiated arthritis, as there is a need for early treatment of RA”. However, we strongly disagree with the use of the 1987 ACR criteria. Until we understand more about the pathogenesis of RA, clinicians will have to rely on clinical judgment and the presence of poor prognostic factors to make decisions about whether to treat aggressively patients presenting with early disease.

BEVERLEY HARRISON
ALAN SILMAN
DEBORAH SYMONDS

ARC Epidemiology Unit, Stamford Building, Oxford Rd, Manchester M13 9PT, UK


---


4 Pincus T, Callahan LF, Burks RA. Most chronic diseases are reported more frequently by individuals with fewer than 12 years of formal education in the age 18–64 United States population. J Chronic Dis 1987;40:865–74.


---

References


4 Pincus T, Callahan LF, Burks RA. Most chronic diseases are reported more frequently by individuals with fewer than 12 years of formal education in the age 18–64 United States population. J Chronic Dis 1987;40:865–74.


Authors’ reply

We agree with Harrison et al that the main difficulty for a rheumatologist in early arthritis is to distinguish progressive rheumatoid arthritis from self limiting disease and other forms of arthritis that do not show a progressive course. Nevertheless, there is also a need in clinical practice for the primary care doctors and the patient to perform, as early as possible, a nosological differentiation between RA and the whole spectrum of other arthropitides and spondarthritides.

We have described the incidence of undifferentiated arthritis to be as high as 54%.

When patients were seen in this early synovitis outpatient clinic between 1984 and 1986, the 1958 American Rheumatism Association (ARA) criteria had not been revised. Expert diagnoses were made with knowledge of the 1958 ARA criteria for the diagnosis of RA but were not the basis of diagnoses. Trained as clinicians, rheumatologists never used the ACR criteria for diagnosis making. Only in retrospect, were the 1987 revised ACR criteria applied. These criteria for classification of RA.

The intention was to investigate the performance of these criteria in early synovitis with a high proportion of undifferentiated and reactive arthritides. Since the performance was good with a high sensitivity (90%) and a high specificity (90%), we suggested, that these criteria could be used not only as classification criteria but also as criteria for the diagnosis of RA.

Criteria should be applied longitudinally at follow up, rather than simply at baseline. We applied criteria cross sectionally on the day of their first visit. We can not present follow up data on the whole group, but of a subgroup of 28 patients with undifferentiated arthritis.

Only two of these patients developed rheumatoid factor negative RA. 15 patients showed complete remission, two showed partial remission and one of the patients had unchanged progressive unclassified arthritis, and one patient had developed ankyllosing spondylitis.

In accordance with our experience, van der Horst-Bruinsma et al have shown, in a special early rheumatoid arthritis clinic, that early diagnosis of RA is possible and reliable. Compared with routine patient care, of 74 patients with definite RA according to the 1987 ACR criteria, diagnosed at two weeks after the first visit, 66 still had definite RA after one year, and in only four patients was the diagnosis changed to systemic lupus erythematosus (one), undifferentiated arthritis (one), gout (one), and probable RA (one). Two patients had died and two were lost to follow up. This shows that the validity is high for the 1987 ACR criteria for differentiating between RA and non-RA arthritides in an early synovitis clinic.

We do not imply that patients who do not fulfill the 1987 ARA criteria do not have RA. If they do not fulfill the criteria at this early stage, we classify them as undifferentiated arthritis. This is a working diagnosis, which can be changed to a definite diagnosis during follow up, but is only rarely necessary, as our experience at the rheumatology clinics show.

The 1987 ACR criteria are not valid for prognostic purposes as Harrison et al stated. Other prognostic factors exist and can easily be applied to patients with RA. But the ACR criteria for RA should be seen as an important means of helping family doctors and general practitioners not trained in rheumatology to make a diagnosis of RA and to differentiate between RA and other forms of arthritides as soon as possible in the course of the disease. Thus by early referral to a rheumatologist an adequate treatment can be started as soon as possible. Even rheumatologists, who are familiar with the criteria used in all controlled trials to establish treatment guidelines, are, in our view, well supported in everyday practice by applying the 1987 ACR criteria to differentiate RA from other forms of arthritides, enabling early diagnosis and treatment decisions.

Efficacy of intra-articular primatised anti-CD4 in resistant rheumatoid knees

An interesting paper was published recently in the *Annals of Rheumatic Diseases* examining the effect of intra-articular administration of primatised anti-CD4 antibody in the knee joints of patients with rheumatoid arthritis and persistent synovitis, unresponsive to treatment. The paper correctly detailed the disappointing results obtained in clinical trials with parenteral treatment with anti-CD4 antibodies, particularly in view of the supposed pivotal role of CD4 positive T cells in the chronic synovial inflammatory response.

The paper showed an apparent improvement in the knee synovitis in patients treated with a low (three patients) and high (seven patients) dose of intra-articular anti-CD4 antibody and no response in two patients treated with placebo, using a combination of magnetic resonance imaging, arthroscopic scoring of the synovitis, and immunohistochemical labelling of the synovial biopsy specimens.

An obvious omission from this paper was any detail of the clinical response of patients to the treatment with anti-CD4 antibody, whether the patients received a low or high dose of the antibody, or if the treatment was given by parenteral or intra-articular route. The paper also fails to state whether the antibody exerted any beneficial effect on the chronic synovial inflammatory response.

Considerable doubt about the central role of the CD4 positive T cell in sustaining the chronic synovial inflammation in rheumatoid arthritis remains and this study has not altered this conclusion.

MALCOLM SMITH

Division of Medicine, Repatriation General Hospital, Daw Park, South Australia 5041,
Authors’ reply

We thank Professor Smith for his interesting comments. Professor Smith refers to an “obvious omission...any doctor or patient derived clinical parameters”. Clearly, we had measured the knee circumference of the target knee in this situation and we were using knee swelling as a clinical parameter; in table 1 of our paper it can be seen that there was no significant change in the knee circumference in any of the treatment or placebo groups during the study. Although we did not show the data in the results section, we stated that there was no statistically significant improvement in the doctor’s assessment of knee synovitis over the study period. Therefore, we do not suggest there was a marked clinical response to treatment in these patients. We agree that there was a marked disparity in the baseline CRP levels within the three groups, but this was a result of randomisation and therefore something over which we had no control.

As regards the changes in MRI measurements, and the quantitative maps showing the reduction in gadolinium uptake, we believe that the trend towards the dose response across these techniques, using articular arthritis, and secondly, as a unique combination of imaging techniques, using arthropathies are adhesion molecules involved in several biological processes. Of interest, their role in the process of adhesion and phagocytosis of apoptotic cells has been recently demonstrated.

Jones and colleagues demonstrated reduced Reiter cells in the synovial fluids from patients with rheumatoid arthritis. This observation is consistent with the hypothesis that Reiter cells play a regulatory part in preventing autoxidation of polymorphonuclear neutrophils (PMN) and thus local tissue damage.

The purpose of this study was to evaluate by histochemical technique whether Reiter cells express CD36 and CD14 in inflammatory synovial fluids.

We analysed the synovial fluids obtained from the knee joints of 10 patients suffering from inflammatory joint diseases of recent onset (<6 weeks). Three patients had serum positive active rheumatoid arthritis, four patients had sero-negative spondyloarthritides (two reactive arthritis, one psoriatic arthritis, one enterovarthritis) and three patients had crystal induced arthritis (two cases of acute gout and one case of acute psogout). Synovial fluids were processed within one hour of aspiration. Two slides were stained with May-Grünewald-Giensa (MGG) reagent. Reiter cells were counted on the basis of the first 500 cells encountered on MGG stained slides. In addition, two cyt centrifuge monolayer preparations were processed for immunohistochemistry using the monoclonal anti-human-CD36 antibody (Boehringer Mannheim-Germany) diluted to 3.5 mg/ml and the monoclonal antihuman monocoyte CD14 antibody (DAKO-Denmark) diluted 1:10 in TRIS-HCL bufer. In brief, specimens were air dried, fixed with acetone and then stored at −70°C until processing. The specimens were incubated for 60 minutes at room temperature with the primary antibody. For the conjugation of peroxidase an En Vision + TM Kit (Dako) was used. The mo no layers were then incubated for five minutes with a prediluted diamino-benzidine solution (DAKO) and counter coloured with Mayer’s haematoxylin. All incubation steps were preceded by washes in 0.1 M PBS (five minutes × three). The slides were examined at 400 × magnification.

Omission of primary antisera, use of normal rabbit serum, or one of subsequent steps in the staining method were included as controls for specificity.

Macrophages as well as Reiter cells could be observed on MGG stained slides. Reiter cells were more abundant in synovial fluids from patients with soro-negative spondyloarthritis and crystal induced arthritis compared with synovial fluids from RA (table 1). On immunohistochemistry preparations, numerous mononuclear cells showed a CD36 positive reaction, while all the Reiter cells observed displayed a positivity for the thrombospondin receptor. CD14+ mononuclear cells outnumbered CD36+ cells; similarly, all the Reiter cells observed were immunoreactive for the anti-CD14 antibody (fig 1A, 1B). Our findings show that Reiter cells do express both CD36 and CD14 adhesion molecules.

CD36 expression on Reiter cells seems to support the notion of the involvement of this receptor in the clearance of apoptotic PMN during synovial inflammation. In vitro data have shown that thrombospondin receptor and CD14 are some of the most important adhesion molecules involved in cell clearance.

The expression of the thrombospondin receptor turns an amateur phagocyte into a professional one. It has been hypothesised that dysregulation of this receptor and the ensuing impairment of inflammatory cell elimination could play a part in inducing chronicity as well as tissue damage and scarring. Recently, CD14 has been demonstrated to mediate recognition and phagocytosis of apoptotic cells. This interaction depends on a region of CD14 that is supposed to be identical to a region that binds bacterial lipopolysaccharide, triggering the release of proinflammatory cytokines from macrophages. On the other hand, the interaction with self components acts as an initial step leading to apoptotic cell elimination. A major role for CD36 in the uptake of apoptotic neutrophils has been recently hypothesised, but it seems likely that micro-environmental modifications could promote the switch from a CD36 dependent pathway to pathways using other adhesion molecules such as CD14. The removal of inflammatory PMN is mediated by several surface molecules and modulated by microenvironmental modifications; it seems to be a crucial, although only partially understood event for the control and resolution of inflammation. Our results suggest that CD14 and CD36 could be involved in the adhesion of the macrophage to the apoptotic cell, the first step of

LETTERS TO THE EDITOR

CD36 and CD14 immunoreactivity of Reiter cells in inflammatory synovial fluids

Reiter cells are macrophages containing ingested polymorph nuclei that are commonly found in most inflammatory synovial fluids. Available data indicate that CD36 and CD14 on human monocyte derived macrophages are adhesion molecules involved in several biological processes. Of interest, their role in the process of adhesion and phagocytosis of apoptotic cells has been recently demonstrated.

Jones and colleagues demonstrated reduced Reiter cells in the synovial fluids from patients with rheumatoid arthritis. This observation is consistent with the hypothesis that Reiter cells play a regulatory part in preventing autoxidation of polymorphonuclear neutrophils (PMN) and thus local tissue damage.

The purpose of this study was to evaluate by histochemical technique whether Reiter cells express CD36 and CD14 in inflammatory synovial fluids.

We analysed the synovial fluids obtained from the knee joints of 10 patients suffering from inflammatory joint diseases of recent onset (<6 weeks). Three patients had serum positive active rheumatoid arthritis, four patients had sero-negative spondyloarthritides (two reactive arthritis, one psoriatic arthritis, one enterovarthritis) and three patients had crystal induced arthritis (two cases of acute gout and one case of acute psogout). Synovial fluids were processed within one hour of aspiration. Two slides were stained with May-Grünewald-Giensa (MGG) reagent. Reiter cells were counted on the basis of the first 500 cells encountered on MGG stained slides. In addition, two cyt centrifuge monolayer preparations were processed for immunohistochemistry using the monoclonal anti-human-CD36 antibody (Boehringer Mannheim-Germany) diluted to 3.5 mg/ml and the monoclonal antihuman monocoyte CD14 antibody (DAKO-Denmark) diluted 1:10 in TRIS-HCL bufer. In brief, specimens were air dried, fixed with acetone and then stored at −70°C until processing. The specimens were incubated for 60 minutes at room temperature with the primary antibody. For the conjugation of peroxidase an En Vision + TM Kit (Dako) was used. The mo no layers were then incubated for five minutes with a prediluted diamino-benzidine solution (DAKO) and counter coloured with Mayer’s haematoxylin. All incubation steps were preceded by washes in 0.1 M PBS (five minutes × three). The slides were examined at 400 × magnification.

Omission of primary antisera, use of normal rabbit serum, or one of subsequent steps in the staining method were included as controls for specificity.

Macrophages as well as Reiter cells could be observed on MGG stained slides. Reiter cells were more abundant in synovial fluids from patients with soro-negative spondyloarthritis and crystal induced arthritis compared with synovial fluids from RA (table 1). On immunohistochemistry preparations, numerous mononuclear cells showed a CD36 positive reaction, while all the Reiter cells observed displayed a positivity for the thrombospondin receptor. CD14+ mononuclear cells outnumbered CD36+ cells; similarly, all the Reiter cells observed were immunoreactive for the anti-CD14 antibody (fig 1A, 1B). Our findings show that Reiter cells do express both CD36 and CD14 adhesion molecules.

CD36 expression on Reiter cells seems to support the notion of the involvement of this receptor in the clearance of apoptotic PMN during synovial inflammation. In vitro data have shown that thrombospondin receptor and CD14 are some of the most important adhesion molecules involved in cell clearance.

The expression of the thrombospondin receptor turns an amateur phagocyte into a professional one. It has been hypothesised that dysregulation of this receptor and the ensuing impairment of inflammatory cell elimination could play a part in inducing chronicity as well as tissue damage and scarring. Recently, CD14 has been demonstrated to mediate recognition and phagocytosis of apoptotic cells. This interaction depends on a region of CD14 that is supposed to be identical to a region that binds bacterial lipopolysaccharide, triggering the release of proinflammatory cytokines from macrophages. On the other hand, the interaction with self components acts as an initial step leading to apoptotic cell elimination. A major role for CD36 in the uptake of apoptotic neutrophils has been recently hypothesised, but it seems likely that micro-environmental modifications could promote the switch from a CD36 dependent pathway to pathways using other adhesion molecules such as CD14. The removal of inflammatory PMN is mediated by several surface molecules and modulated by microenvironmental modifications; it seems to be a crucial, although only partially understood event for the control and resolution of inflammation. Our results suggest that CD14 and CD36 could be involved in the adhesion of the macrophage to the apoptotic cell, the first step of

Table 1 The number of Reiter cells calculated on the first 500 cells encountered on May-Grünwald-Giemsa stained slides

<table>
<thead>
<tr>
<th>Type of Arthritis</th>
<th>Reiter cells (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA (n=3)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>SsA (n=4)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td>CIA (n=3)</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
</tbody>
</table>

RA: rheumatoid arthritis, SsA: soro-negative spondyloarthritis, CIA: crystal induced arthritis.
Non-periodic leg pain in patients with familial Mediterranean fever

Familial Mediterranean fever (FMF) is characterized by recurrent bouts of fever and peritonitis, pleuritis, arthritis or erysipelas-like skin disease. Between the episodes, FMF patients are free of symptoms and appear healthy. However, interestingly we observe leg complaints after prolonged standing or sitting, or both, in FMF patients, who usually experience these painful manifestations during evenings or after long distance bus trips. Thus we conducted a questionnaire study on 46 FMF patients (age, 21.3 (0.2) years; F: M, 2: 38) and 180 healthy male subjects (age, 21.3 (0.2) years to ascertain the frequency of such complaints, and some of FMF patients were also included in a test to provoke these symptoms. Table 1 shows the questionnaire. Positive cases were also questioned for the presence of swelling or redness during these painful periods, and whether these complaints followed by an episode. Although 14 of the 180 healthy subjects responded positively to the first question (question A), none of them were considered to be positive after further questions (questions B). All FMF patients reported foot or leg pain after prolonged standing periods (first part of question A). They described that, at the onset, the pain was merely confined to the mid-foot, however other sites (the ankles, the calves, the knees or even the thighs) were involved in an additive manner as the intensity of pain increased unless resting ensued. Thirty five FMF patients have experienced foot pain (with or without subcutaneous swelling) during or after long distance bus travel and they also described an area of redness, which typically located on the ankles, mid-foot or subcutaneous swelling during the episodes. Thirty five FMF patients have described a low grade fever subsequent to the episodes with severe lower extremity symptoms. In provocation test, 30 volunteer male FMF patients (age, 21.2 (1.8)) without proteinuria and 30 volunteer male healthy subjects (age, 21.1 (0.8)) were kept in an upright position (standing, walking or dependent sitting) for 3 hours. At the beginning, all participants were symptom free and none of them had any other disorder that may cause foot pain. Thirty FMF patients were receiving colchicine treatment. Bilateral ankle and mid-foot circumference differences were measured from the marked points at the onset and the termination of the test. The mean change in circumference per measurement site (mean (SD)) was 3.0 (2.7) mm and 1.3 (1.5) mm in the patient and the control group, respectively. Although the comparison was statistically significant (p=0.014; Mann-Whitney U), we think that our method was not reliable to detect those small changes precisely. At the end of the provocation test, none of the healthy controls had lower extremity pain or tenderness. After one visit, all FMF patients had intense foot or calf pain, which interfered with walking. Tenderness was so profound that it could be elicited even by a gentle touch. Widespread tenderness was detected in 12 of 17 patients, which may be an inciting factor for episodes. Although swelling was not noticed in anyone, focal erythematicous areas (not erysipelas) were seen in five patients. After five hours of resting, palpation showed that tenderness was sustained (14 widespread and 16 localised). A localised pain and tenderness was also developed in the symptom free patient. Colchicine use did not change the results of provocation test (p=0.240; Fisher’s test). Although leg pain induced by exercise or prolonged standing has already been discussed in FMF patients, we are unaware of any report about leg pain and swelling episodes after prolonged sitting in these patients. Increased hydrostatic pressure in the lower extremities may be the main factor responsible for those symptoms experienced during bus trips. It was suggested that FMF is related to catecholamine metabolism as metaraminol infusion may provoke an acute episode, and episodes may be prevented by prazosin hydrochloride, as reported recently. Leucocytes may need adequate perfusion (driving) pressure to pass through capillaries in microcirculation. These findings raise the possibility that catecholamines may increase the hydrostatic pressure of capillary bed, which may be an inciting factor for episodes. Our findings show that an inflammatory process involving lower extremities occurs after prolonged standing and sitting periods in FMF patients. We think that genetically low level of inhibitory activity (that is, mutated pyrin) may not be able to compensate the inflammatory reaction that is probably initiated in a stressful microenvironment caused by not only microtrauma, but also increased hydrostatic pressure.

We greatly indebted to Professor Hasan Yazici for constructive criticism and help in preparation.

N D C
Division of Rheumatology, Department of Internal Medicine, G Hilmi School of Medicine, Ankara, Turkey

Correspondence to: Dr Dinc, GATA Romatoloji Bilim Dalı, Etilik, 06010 Ankara, Turkey

Table 1 Questionnaire on lower extremity complaints

<table>
<thead>
<tr>
<th>A</th>
<th>Have you ever had foot or leg pain events after prolonged standing and/or bus travel lasted more than six hours?</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Has it been existed since childhood or adolescence?</td>
</tr>
<tr>
<td>C</td>
<td>Does it occur mostly after a period of prolonged standing or sitting?</td>
</tr>
<tr>
<td>D</td>
<td>Does it occur mostly bilateral?</td>
</tr>
<tr>
<td>E</td>
<td>Does it persist at least 30 minutes after rest?</td>
</tr>
</tbody>
</table>

If all of the answers are yes, then the case was considered to be positive.

CORRECTION

Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex (P Demeter et al. Ann Rheum Dis 2000;59:211–16). We regret that the references in this article are incorrectly numbered. Owing to the splitting of reference 7, references numbered from 9 onwards in the text are listed as 10 onwards in the reference list.
Diagnostic evaluation of classification criteria for RA and reactive arthritis

BEVERLEY HARRISON, ALAN SILMAN and DEBORAH SYMMONS

Ann Rheum Dis 2000 59: 397-398
doi: 10.1136/ard.59.5.397

Updated information and services can be found at: http://ard.bmj.com/content/59/5/397

References

This article cites 10 articles, 2 of which you can access for free at: http://ard.bmj.com/content/59/5/397#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/